search
Back to results

Spyglass DS Peroral Cholangioscope Guided LL or EHL Versus BML for Endoscopic Removal of Complicated Bile Duct Stones

Primary Purpose

Biliary Stones

Status
Recruiting
Phase
Not Applicable
Locations
Hong Kong
Study Type
Interventional
Intervention
Spyglass DS cholangioscope
BML
Sponsored by
Chinese University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Biliary Stones focused on measuring Spyglass DS, Laser lithotripsy, Endoscopic retrograde cholangiopancreatography

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with complicated biliary stones
  • Patients older than 18 years old
  • Patients where informed consent can be obtained

Exclusion Criteria:

  • Patients who cannot give informed consent
  • Patients under 18 years old
  • Pregnant or lactating patients
  • Patient with altered gastrointestinal/biliary anatomy
  • Patients with distal CBD malignant stricture from intrinsic or extrinsic causes
  • Patients with ongoing cholangitis or biliary pancreatitis
  • Patient with refractory bleeding tendencies (Platelet count <50,000/mm3 or International Normalized Ratio >1.5 despite correction with platelet or fresh frozen plasma transfusions)
  • Patients with intrahepatic segmental stones
  • Patients with contraindications to endoscopy due to comorbidities

Sites / Locations

  • Endoscopy Centre, Prince of Wales HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

LASER ARM

CONVENTIONAL ARM

Arm Description

Spyglass DS cholangioscope guided laser or electrohydraulic lithotripsy

Stone removal by conventional techniques, for example BML, without laser lithotripsy

Outcomes

Primary Outcome Measures

Overall rate of endoscopic bile duct stone clearance
Overall rate of endoscopic bile duct stone clearance

Secondary Outcome Measures

Technical feasibility
Technical feasibility defined as successful introduction of cholangioscope into the CBD, visualisation and laser targeting of stone
Incidence of adverse events
Incidence of adverse events
Need for and number of additional procedures for stone clearance
Need for and number of additional procedures for stone clearance

Full Information

First Posted
July 31, 2017
Last Updated
August 20, 2023
Sponsor
Chinese University of Hong Kong
search

1. Study Identification

Unique Protocol Identification Number
NCT03244163
Brief Title
Spyglass DS Peroral Cholangioscope Guided LL or EHL Versus BML for Endoscopic Removal of Complicated Bile Duct Stones
Official Title
Randomized Controlled Trial of Spyglass DS Peroral Cholangioscope Guided Laser Lithotripsy or Electrohydraulic Lithotripsy Versus Conventional Basket Mechanical Lithotripsy for Endoscopic Removal of Complicated Bile Duct Stones
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 14, 2016 (Actual)
Primary Completion Date
June 2026 (Anticipated)
Study Completion Date
December 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study aims to compare the overall rate of endoscopic clearance of complicated bile duct stones by Spyglass DS peroral cholangioscopy guided holmium:YAG laser/electrohydraulic lithotripsy versus conventional BML.
Detailed Description
Currently, complicated bile duct stones are removed during endoscopic retrograde cholangiopancreatography (ERCP) by conventional mechanical lithotripsy, which means using a metal wire basket to capture the stone and crush it to make it easier to remove. This is successful in approximately 70% of patients, with the success rate inversely correlated to the size of the stone. Unsuccessful stone removal would require additional endoscopic, percutaneous or surgical interventions. Spyglass DS peroral cholangioscope-guided holmium:YAG laser/electrohydraulic lithotripsy is a recent alternate method for managing complicated bile duct stones. Also performed during ERCP, a thin flexible camera (called Spyglass DS peroral cholangioscope) is inserted into the bile duct to visualize the stone which can then be targeted by a laser beam for fragmentation (also known as laser lithotripsy). The smaller pieces are then removed. Direct comparisons of these procedures' efficacy however have not been performed. The purpose of this study is to compare the efficacy and safety of Spyglass DS peroral cholangioscope-guided holmium:YAG laser/electrohydraulic lithotripsy (the laser arm) versus conventional basket mechanical lithotripsy alone (the conventional arm) for fragmentation and clearance of complicated bile duct stones.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Biliary Stones
Keywords
Spyglass DS, Laser lithotripsy, Endoscopic retrograde cholangiopancreatography

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
86 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LASER ARM
Arm Type
Experimental
Arm Description
Spyglass DS cholangioscope guided laser or electrohydraulic lithotripsy
Arm Title
CONVENTIONAL ARM
Arm Type
Active Comparator
Arm Description
Stone removal by conventional techniques, for example BML, without laser lithotripsy
Intervention Type
Device
Intervention Name(s)
Spyglass DS cholangioscope
Intervention Description
The 1.8Fr holmium:YAG laser fiber (Lumenis, Yokneam, Israel) will be inserted into the cholangioscope's working channel for lithotripsy under direct visualization. An EHL probe may alternatively be used depending on availability. Lithotripsy is applied until fragments of the targeted stone are no longer lumen filling, and can be dispersed easily with fluid irrigation. Fragmented stones are then removed by a combination of conventional techniques. To confirm stone clearance, the Spyglass DS cholangioscope will be re-introduced, and the bile duct will be examined for residual stones from the confluence of the right and left intrahepatic ducts to the papillary opening
Intervention Type
Device
Intervention Name(s)
BML
Intervention Description
Biliary sphincterotomy with/without EPBD to the size of the lower bile duct with a limit of 15mm will be performed. Stones are removed by a combination of conventional BML, extraction balloon and/or baskets, without laser lithotripsy. An occlusion cholangiogram is performed to confirm stone clearance. In cases where stone clearance is incomplete, a plastic biliary stent bridging the stone will be inserted for temporary drainage until definitive management, usually within one month.
Primary Outcome Measure Information:
Title
Overall rate of endoscopic bile duct stone clearance
Description
Overall rate of endoscopic bile duct stone clearance
Time Frame
Intraoperative
Secondary Outcome Measure Information:
Title
Technical feasibility
Description
Technical feasibility defined as successful introduction of cholangioscope into the CBD, visualisation and laser targeting of stone
Time Frame
Intraoperative
Title
Incidence of adverse events
Description
Incidence of adverse events
Time Frame
30 days
Title
Need for and number of additional procedures for stone clearance
Description
Need for and number of additional procedures for stone clearance
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with complicated biliary stones Patients older than 18 years old Patients where informed consent can be obtained Exclusion Criteria: Patients who cannot give informed consent Patients under 18 years old Pregnant or lactating patients Patient with altered gastrointestinal/biliary anatomy Patients with distal CBD malignant stricture from intrinsic or extrinsic causes Patients with ongoing cholangitis or biliary pancreatitis Patient with refractory bleeding tendencies (Platelet count <50,000/mm3 or International Normalized Ratio >1.5 despite correction with platelet or fresh frozen plasma transfusions) Patients with intrahepatic segmental stones Patients with contraindications to endoscopy due to comorbidities
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
John C Wong, MD
Phone
(852)35052931
Email
jctwong@cuhk.edu.hk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James LAU, MD
Organizational Affiliation
Chinese University of Hong Kong
Official's Role
Principal Investigator
Facility Information:
Facility Name
Endoscopy Centre, Prince of Wales Hospital
City
Hong Kong
State/Province
NT
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
John C Wong, MD
Phone
(852)35052931
Email
jctwong@cuhk.edu.hk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Spyglass DS Peroral Cholangioscope Guided LL or EHL Versus BML for Endoscopic Removal of Complicated Bile Duct Stones

We'll reach out to this number within 24 hrs